Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pz-1 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Pz-1 (and its second-generation variant P28z) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Memorial Sloan Kettering Cancer Center for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The therapy involves the genetic modification of a patient's own T cells to express a CAR that targets prostate-specific membrane antigen (PSMA), a cell-surface protein highly expressed on prostate cancer cells and the neovasculature of various solid tumors. The CAR construct utilizes a single-chain variable fragment (scFv) derived from the J591 monoclonal antibody. The Pz-1 construct is a first-generation CAR containing the CD3ζ signaling domain, while the P28z variant incorporates the CD28 costimulatory domain to improve T-cell activation, expansion, and persistence. In clinical trials (NCT01140373), these engineered T cells are administered intravenously following lymphodepleting chemotherapy with cyclophosphamide.
- Other names
- autologous PSMA-targeted engineered T cellsJ591-CAR T cellsJ-591-CAR T cellsJ 591-CAR T cellsPSMA-targeted CAR T-cells
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on Pz-1 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pz-1 CAR-T cells.